New drug combo aims to boost stomach cancer surgery success
NCT ID NCT07023315
Summary
This study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy improves outcomes for people with operable stomach or gastroesophageal cancer. About 760 participants will receive the drug combination or a placebo, both before and after their surgery. The main goals are to see if this approach helps patients live longer without their cancer returning and if it is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, China
Contact
-
Fujian Provincial Cancer Hospital
RECRUITINGFuzhou, Fujian, China
Contact
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100143, China
Contact
Contact
-
Tianjin Provincial Tumor Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.